$GH

CLARK IAN T sold $2.3M of GH (indirect holdings)

CLARK IAN T sold 14,180 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $158.92 ($158.80–$158.98, $2.25M total) across 2 trades on 2026-08-04.

Original reporting
SEC EDGAR · CLARK IAN T
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 14,180 shares (about $2.25M) at roughly $158.8 to $159.0 per share, with holdings after the sale of 2,975 shares.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but it does not introduce new company fundamentals or guidance.

03

What to watch

No 10b5-1 plan is disclosed here, but the article also provides no context on total holdings, prior sale cadence, or whether other insiders are buying or selling around the same period.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-05, trades dated 2026-08-04

Background

This is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported by a director.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Clark Ian T sold $2.25M of GH shares via two open-market trades at about $158.9 on 2026-08-04.

Expected impact

Limited near-term impact; any effect is likely transient unless followed by additional insider selling or new company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a moderate dollar value, but it does not include new operational, financial, or regulatory information.

Market effects

Minimal; insider selling at one healthcare diagnostics name does not materially change sector expectations.

None indicated.

None indicated.

Counterpoint

The sale may be driven by personal liquidity needs rather than a view on business prospects, especially given the lack of a stated fundamental catalyst in the filing.

Key entities

  • Guardant Health, Inc.

    Company whose shares were sold by an insider director via open-market transactions.

  • CLARK IAN T

    Director who sold 14,180 shares of GH on 2026-08-04, reported on 2026-08-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.